NEWS

Inspiring New Stories

Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:

Press Releases

  • 05/21/21

    Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

  • 05/10/21

    Halozyme Reports First Quarter 2021 Results

  • 04/29/21

    Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

  • 04/20/21

    Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

  • 02/24/21

    Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

  • 02/10/21

    Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

  • 01/15/21

    Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

  • 01/11/21

    Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

  • 01/04/21

    Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference